CareLit · DOI-Nachweis · Geburtshilfe und Frauenheilkunde
EZH2 inhibition sensitizes BRCA1-deficient breast tumors to the PI3K inhibitor BKM120
DOI 10.1055/s-0036-1593269
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Puppe, M van de Ven, E van der Burg, U Boon, O van Tellingen, P Bouwman, P Mallmann, R Schmutzler, M van Lohuizen, J Jonkers
ZeitschriftGeburtshilfe und Frauenheilkunde
Ausgabe10/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Current treatment options for BRCA1-deficient breast cancer are limited highlighting the need for novel targeted therapies. EZH2 is an epigenetic repressor through its trimethylase activity of H3K27me3 and associated with highly aggressive types of breast cancer. Our group previously demonstrated that EZH2 is overexpressed in BRCA1-deficient breast tumors and a promising target for this subtype. Recently…
Zitieren
Zitierempfehlung
J Puppe, M van de Ven, E van der Burg, U Boon, O van Tellingen, P Bouwman, P Mallmann, R Schmutzler, M van Lohuizen, J Jonkers (2016) EZH2 inhibition sensitizes BRCA1-deficient breast tumors to the PI3K inhibitor BKM120. Geburtshilfe und Frauenheilkunde (10). https://doi.org/10.1055/s-0036-1593269
Mit CareLit weiterarbeiten